First mRNA cancer vaccine cuts melanoma recurrence risk by 42% in Phase III trial
An mRNA cancer vaccine just cleared its biggest test yet.
The results from the first successful Phase III trial of a personalized mRNA cancer vaccine landed this week, and the field of RNA medicine had a lot more to say alongside it.
๐ฏ The mRNA Cancer Vaccine Era Has a Phase III Win
- Adding the personalized mRNA vaccine intismeran autogene to the checkpoint drug pembrolizumab after melanoma surgery reduced the risk of disease recurrence or death by 42% compared to pembrolizumab alone, according to results from the Phase III INTerpath-001 trial presented at ESMO 2026.
- The vaccine is individualized โ it's designed around each patient's own tumor mutations, meaning it targets neoantigens specific to that person's cancer.
- This is a Phase III result, not a pilot. That distinction matters: earlier-phase wins in cancer vaccines have stalled before, and this one held up at scale.
Why it matters: Personalized mRNA cancer vaccines have been a compelling idea for years. A Phase III win in melanoma is the clearest evidence yet that the concept translates beyond the lab โ and it puts pressure on every other tumor type to follow.
Key Findings
๐ฆ Bird Flu Vaccine Works Better With a Longer Wait Between Doses
- In a Phase I trial of 212 healthy adults, an H5N1 self-amplifying mRNA vaccine (ARCT-2304) given on an 8-week schedule produced stronger and more durable antibody responses than the same vaccine given 4 weeks apart โ with neutralizing antibodies still significantly elevated 6-7 months after the second dose.
- The vaccine encodes both hemagglutinin and neuraminidase proteins, and also triggered T-cell responses. Side effects were mostly mild to moderate and transient.
๐ Where mRNA Goes After a Vaccine Shot Is More Complicated Than Expected
- A rat study tracking three common lipid nanoparticle formulations after subcutaneous injection found that mRNA components and lipid components don't always travel together through the lymphatic system โ lipid components showed up in thoracic lymph at 3-4x higher rates than the mRNA they were supposed to carry.
- Concentrations of all components were 10 to 1,000-fold higher in thoracic lymph than in blood after subcutaneous injection, suggesting the lymphatic route is the primary highway โ but mRNA appears to get lost along the way.
๐งฌ A Modified Nucleoside Boosted Antigen Output in Immune Cells Up to 20-Fold
- Swapping standard uridine for a chemically modified version (N1-methylpseudouridine) in mRNA encoding tumor antigens increased protein production in human dendritic cells by up to 20-fold compared to unmodified mRNA.
- Those antigen-loaded dendritic cells then successfully primed cancer-targeting T cells from healthy donor blood, with the resulting T cells showing strong killing activity against tumor cell lines expressing the target antigens.
๐ Moderna and Pfizer Vaccines Differ in How Quickly mRNA Breaks Down in Blood
- Analyzing serial blood samples from 73 vaccinated humans, researchers found that intact vaccine mRNA declined about 2-fold faster after Moderna mRNA-1273 than after Pfizer-BioNTech BNT162b2 vaccination.
- The lipid carrier for BNT162b2 persisted longer than its associated intact mRNA, while Moderna's SM-102 lipid tracked more closely with mRNA decay โ a platform-specific difference with potential implications for how long each vaccine produces spike protein.
๐ค An AI Tool Improved mRNA Stability Prediction by 13% โ and Redesigned a Vaccine Sequence
- RNASTOP, a deep learning framework combining neural networks with heuristic search, outperformed the previous top model on a standard mRNA degradation benchmark by 13% in accuracy.
- Applied to codon optimization for a varicella-zoster virus vaccine sequence, it reduced the minimum free energy of the mRNA structure by 75.73% while maintaining translation efficiency โ a design move that could extend shelf life and potency.
๐งช Exosome-Mimicking Nanoparticles Delivered Gene Therapy to Pancreatic Tumors Without Liver Buildup
- Researchers tested an experimental combination treatment in mouse models of pancreatic cancer.
- In mouse models of pancreatic ductal adenocarcinoma โ one of the hardest-to-treat solid tumors โ the particles accumulated preferentially in tumors rather than the liver and drove significant tumor regression with repeated intravenous dosing.
Implications
The Phase III melanoma result reframes personalized mRNA cancer vaccines from promising to proven โ at least in one tumor type. The open question now is whether the same approach holds in cancers with fewer mutations and colder immune environments, where neoantigens are harder to find and T cells harder to activate.
Studies in this issue
Primary sources used for this newsletter.
- First mRNA Cancer Vaccine Shows Success in Final Phase Trialmain storyCancer discovery2026-10-26PMID 42929716
- How Three mRNA Lipid Nanoparticle Vaccines Behave and Stay Intact in Human Bloodkey findingACS nano2026-10-27PMID 42937588
- Longer gaps between doses improve lasting protection of a self-boosting mRNA vaccine against pandemic H5N1 flukey findingNature communications2026-10-26PMID 42928290
- Predicting and Improving mRNA Chemical Stability Using Deep Learningkey findingGenomics, proteomics & bioinformatics2026-10-26PMID 42928593
- How mRNA-lipid nanoparticles enter the lymph system and spread through the body after injection into veins or under the skinkey findingJournal of controlled release : official journal of the Controlled Release Society2026-10-26PMID 42933668
- Safe RNA and Chemotherapy Delivery to Tumors Outside the Liver Using Cholesterol-Free Nanoparticles Inspired by Natural Cell Particleskey findingAdvanced healthcare materials2026-10-27PMID 42935085
- Modified mRNA in Immune Cells Helps Produce Effective Cancer-Fighting T Cellskey findingInternational journal of molecular sciences2026-10-27PMID 42941960
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.